PENELOPE: TAR-200 Shows Deeper Tissue Penetration vs Standard Intravesical Therapy

Sia Daneshmand, MD, discusses the key findings from the PENELOPE study he presented at the 25^th Annual Meeting of the Society of Urologic Oncology, which evaluated the tissue penetration of gemcitabine metabolites delivered via the TAR-200 device compared to standard intravesical installation. He explains how TAR-200 achieves sustained drug release for up to 96 hours, delivering active metabolites into deeper bladder tissue layers. Dr. Daneshmand highlights the potential clinical advantages of TAR-200, particularly in addressing high-risk or BCG-unresponsive non-muscle-invasive bladder cancer. He also explores the next steps in TAR-200’s development, its role in ongoing clinical trials, and future research directions aimed at optimizing its use in bladder cancer treatment.